Rough waters for active life science IPO market in 2013 with drugs valued above diagnostics
This article was originally published in Scrip
Executive Summary
So far 2013 has been an active year for US life science initial public offerings, but it's been a rocky month and a half: five companies registered IPOs with the US Securities and Exchange Commission (SEC), four firms priced their offerings, and three cancelled their IPO plans.